<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paradigm-based treatment approaches for management of burn pain</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paradigm-based treatment approaches for management of burn pain</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Paradigm-based treatment approaches for management of burn pain</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shelley Wiechman, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul I Bhalla, MBChB, FRCA, FFPMRCA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc G Jeschke, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13089398"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pain management is a central component of the treatment of patients with burns. Despite advances in burn care, management of burn pain is often inadequate during the acute and chronic rehabilitation phases of burn care [<a href="#rid1">1</a>]. Pain is among the most common causes of distress during the first year after recovery and, hence, should be aggressively managed [<a href="#rid2">2,3</a>]. Burn pain management is typically based upon clinical experience and clinician and/or institutional preference, since available evidence is insufficient to clearly support one approach [<a href="#rid4">4</a>]. </p><p>The approach to the management of patients with acute, background, procedural, and chronic pain secondary to burns will be discussed here. An overview of the pharmacologic and nonpharmacologic treatment options for managing burn pain is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching"</a>.)</p><p class="headingAnchor" id="H518435340"><span class="h1">BURN PAIN PARADIGM</span><span class="headingEndMark"> — </span>A burn pain paradigm guides the use of analgesics for management of the different phases and variability of burn pain [<a href="#rid5">5</a>]. This paradigm is based upon five phases of burn pain occurrence and includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background pain</strong> – Pain that is present while the patient is at rest, results from the thermal tissue injury itself, and is typically of low-to-moderate intensity and long duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedural pain</strong> – Brief but intense pain that is generated by wound debridement and dressing changes and/or rehabilitation activities (eg, physical therapy and occupational therapy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breakthrough pain</strong> – Unexpected spiking of pain levels that occurs when current analgesic effects are exceeded, either at rest, during procedures, or with anxiety. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative pain</strong> – A predictable and temporary increase in pain that occurs after burn excision, donor skin harvesting, and grafting due to the creation of new and painful wounds in the process. The duration of pain is typically two to five days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic pain</strong> – Pain that lasts longer than three to six months or remains after all burn wounds and skin graft donor sites have healed. The most common form of chronic pain is neuropathic pain, which is the result of damage sustained by the nerve endings in the skin. </p><p></p><p class="headingAnchor" id="H92728281"><span class="h1">CHALLENGES IN MANAGING BURN PAIN</span><span class="headingEndMark"> — </span>Acute and chronic burn pain is challenging to treat because of multiple components that must be addressed in addition to the changing patterns of pain with time: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variability of pain</strong> – Burn pain is variable among patients and within each individual. Adequate pain management must be matched with the current situation and be flexible enough to allow for predictable and unpredictable changes. As an example, burn pain can be mild when the burn sites are undisturbed (background pain), become severe with dressing changes and physical therapy (predictable procedural pain), and be interspersed with periods of excruciating pain at unpredictable times (unpredictable breakthrough pain, eg, at night). Psychosocial factors, particularly those relating to the circumstances of a burn injury, may have a significant impact on the individual pain experience.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing of analgesics</strong> – Opioid analgesic dosing in pediatric patients is based on patient weight, which is variable in the burn patient due to physiologic fluid shifts. In adults, opioid response may be variable depending on existing tolerance and may be limited by side effects including respiratory depression, sedation, pruritus, and constipation. (See  <a class="medical medical_review" href="/z/d/html/818.html" rel="external">"Hypermetabolic response to moderate-to-severe burn injury and management", section on 'Hypermetabolic response'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong> – Burn injuries result in variable and often unpredictable changes in volume of distribution and clearance of anesthetics and analgesics, including <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid6">6</a>]. In addition, renal and hepatic function may be compromised in patients with burn injuries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Route of drug administration</strong> – Options include enteral (oral, rectal, gastric via feeding tube), intravenous, inhalational, transmucosal, transdermal, intramuscular, and perineural. The enteral route is generally preferred for management of background pain and in the outpatient setting. The intravenous route generally provides rapid onset but shorter duration of pain relief and is used for severe background pain, procedural/postoperative pain, or breakthrough pain; monitoring of vital signs is mandatory when intravenous opioids are used. </p><p></p><p class="bulletIndent1">Transmucosal immediate-release <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> has been used for the management of procedural pain in burns patients. However, it is approved for use in the United States only for breakthrough pain in opioid tolerant patients with cancer; we no longer use it for breakthrough pain in our burn center. Transmucosal <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> is used for background pain in patients with substance use disorder or in those who are sensitive to full agonists (eg, older adults). Regional anesthesia is useful for inpatients [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioid tolerance</strong> – Tolerance to analgesic effects generally occurs after more than two weeks of opioid use. The frequency of opioid tolerance has not been objectively documented in burn patients, but clinical experience is that the majority of burn patients receiving opioids on a daily basis develop analgesic tolerance during the initial weeks of treatment [<a href="#rid5">5</a>], possibly due to pharmacodynamic changes at the opioid receptor [<a href="#rid8">8</a>]. Over time, a higher dose of medication is needed to achieve the same level of pain relief. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperalgesia</strong> – Hyperalgesia is an increased sensitivity to pain and is induced by the acute inflammatory response of a burn injury. Primary hyperalgesia occurs in the tissues directly damaged by the burn. Secondary hyperalgesia occurs in the normal tissues adjacent to the burn. Continued or repeated painful stimuli associated with background pain or repeated procedural pain can cause central nervous system sensitization that amplifies the pain experience via hyperexcitability of pain pathways [<a href="#rid9">9</a>]. Such pain may be opioid resistant and become irreversible and thus contribute to ineffective opioid analgesia [<a href="#rid10">10</a>]. Patients with a history of opioid use may experience hyperalgesia, and the pain management protocol will need to be adjusted accordingly. Opioid-induced hyperalgesia is a form of hyperalgesia caused by exposure to opioids, meaning patients receiving these drugs paradoxically become more sensitive to painful stimuli [<a href="#rid11">11</a>]. </p><p></p><p class="headingAnchor" id="H92728594"><span class="h1">DRUGS AND DOSING</span><span class="headingEndMark"> — </span>Drug options and dosing for opioids, nonopioids, benzodiazepines, and adjuvant analgesics are provided separately. (See  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient"</a> and  <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults"</a> and  <a class="medical medical_review" href="/z/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H92728756"><span class="h2">Optimizing pharmacotherapy</span><span class="headingEndMark"> — </span>The principles for optimizing opioid pharmacotherapy in burn patients are [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Treat burn pain based upon the five components of the burn pain paradigm: background, procedural, breakthrough, postoperative, and chronic. (See <a class="local">'Burn pain paradigm'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individualize doses, set a flexible dosing schedule, and use frequent dose adjustments as needed to account for variability in analgesic requirements.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assess and document the effectiveness of the pain regimen at regular intervals to adjust doses and dosing intervals. Assessment should use a validated, reproducible tool to measure pain intensity at rest and during movement. Tools are available for children as well as cognitively impaired adults. Additionally, assessment of pain management should focus more on comfort, function, and sleep rather than unidimensional pain scores [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitor side effects of analgesia and take steps to prevent or treat them rather than undertreating pain. Common examples include treating epidural-induced hypotension, or switching from <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> to <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> in order to mitigate nausea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use nonopioid drugs in conjunction with opioids to enhance analgesia and reduce risks of opioid side effects. (See  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Pharmacologic treatment options'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitor anxiety and changes in mood and consider early psychological support or an anxiolytic for procedures, if indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apply nonpharmacologic interventions to complement, not replace, systemic analgesia. (See  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Nonpharmacologic treatment options'</a>.)</p><p></p><p class="headingAnchor" id="H92728112"><span class="h1">PARADIGM-BASED MANAGEMENT</span><span class="headingEndMark"> — </span>We, and many other burn centers, advocate a structured approach to analgesia that incorporates both pharmacologic and nonpharmacologic therapies, targets the specific clinical pain settings unique to the burn patient, and is individualized to meet specific patient needs and institutional capabilities [<a href="#rid13">13-15</a>]. The sections below provide an approach to treatment of burn pain based upon the five phases of the burn pain paradigm. </p><p>Selection of an analgesic regimen is based upon the clinical setting, the effectiveness of the approach in alleviating pain and improving function, and clinician and institutional preferences. No regimen is appropriate in all settings, and there is no high-quality evidence that any particular regimen is more effective than another. (See  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Pharmacologic treatment options'</a> and  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Nonpharmacologic treatment options'</a>.)</p><p>In pediatric patients, in whom risks from analgesia and clinical unfamiliarity are elevated, the use of a weight-based medication worksheet (placed at the bedside and in the patient record) containing all analgesic and resuscitation drugs provides a supplemental safeguard against accidental overdose [<a href="#rid16">16</a>]. </p><p class="headingAnchor" id="H13088214"><span class="h2">Background pain</span><span class="headingEndMark"> — </span>Background pain is expected to decrease with time as the burn wound and associated donor skin graft sites heal. Titrating pain management to functional status is vital, and along with regular assessment of pain, it is important to ask about activity level and sleep. Analgesia can be tapered as the pain lessens in severity and frequency. The optimal treatment of background pain relies on regular or scheduled multimodal analgesia in order to maintain stable plasma drug concentrations and to mitigate side effects of any one agent [<a href="#rid5">5</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic approaches</strong> (see  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Pharmacologic treatment options'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral administration on a regular schedule of nonsteroidal anti-inflammatory agents (NSAIDs) and <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous (IV) opioid administration, such as patient-controlled analgesia (PCA). This may be appropriate earlier on following a burn injury when opioid requirements are usually higher or where the enteral route is unavailable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral administration of immediate release opioids on a regular, "as required" schedule. A number of burns centers have traditionally used long-acting opioids such as <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> for background pain as it is a long-acting agent with N-Methyl-D-Aspartate (NMDA) receptor antagonist properties. However, there appears to be an association between the use of long-acting opioids and an increased risk of progression to long-term opioid use [<a href="#rid17">17</a>]. While methadone is still used for acute pain in our burns center, its use has decreased, and patients who are put on it are monitored closely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic approaches</strong> (see  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Nonpharmacologic treatment options'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Relaxation techniques including meditation, progressive muscle relaxation, deep breathing, and guided imagery</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypnosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Information provision </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive restructuring</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enhanced coping skills </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positioning patients for comfort and to account for areas of hyperalgesia or allodynia</p><p></p><p class="headingAnchor" id="H2458216717"><span class="h2">Breakthrough pain</span><span class="headingEndMark"> — </span>Breakthrough pain occurs when the comfort provided by background pain management is exceeded and may manifest as sudden, more intense spikes of pain [<a href="#rid18">18</a>]. Breakthrough pain can result from an increase in activity level, development of opioid tolerance, and/or changes in the burn wound that increase pain (eg, proliferation of epidermal skin buds during the spontaneous burn healing process, burn wound infection). Adjustments to the pharmacologic and/or nonpharmacologic pain management should be made after a thorough history and examination to determine the most likely cause. Questions about the site, timing, severity, and character of the pain, as well as exacerbating and alleviating factors, can aid management strategies. As an example, pain related to increased activity level may be managed by timing an extra dose of analgesia and by educating the patient about pacing themselves to avoid under- and overactivity. Opioid tolerance may be managed by a change in agent, often referred to as opioid rotation [<a href="#rid19">19</a>]. New pathology, such as wound infection, may warrant a brief increase in opioid dosing and/or addition of new analgesic modalities such as NSAIDs for inflammatory pain or gabapentinoids for neuropathic pain [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1552651524"><span class="h2">Postoperative pain</span><span class="headingEndMark"> — </span>Increased nociceptive pain following surgery may require a short-term (approximately one to four days) increase in background opioid analgesic administration or even a switch to IV PCA. Other strategies include the use of continuous regional block techniques, IV <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> infusions, and 24- to 48-hour low-dose <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> infusions [<a href="#rid7">7,21-23</a>]. (See  <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults"</a>.)</p><p class="headingAnchor" id="H13088221"><span class="h2">Procedural pain</span><span class="headingEndMark"> — </span>Anticipatory anxiety is an important issue that can develop with the repeated performance of wound care. When adequate analgesia is not provided for an initial, painful procedure, the effectiveness of analgesia for subsequent procedures is reduced, in large part due to anticipatory anxiety and heightened arousal [<a href="#rid24">24,25</a>]. Thus, efforts to provide effective procedural burn pain management should begin with the first wound care procedure. </p><p>Dressing changes produce pain that is more intense and shorter in duration than background pain and are optimally managed using a combination of sedatives, analgesics, and anxiolytics [<a href="#rid26">26</a>]. Sedation should be considered as a continuum from mild (anxiolytic only with no change in cognitive response) to moderate (depressed consciousness but responds purposely to verbal or tactile stimulation) to deep (hard to rouse, responds purposely to intense, painful stimulation) to full general anesthesia (no response attainable to stimulation). Administration of moderate or deep sedation should follow institutional guidelines developed for safety and efficacy. Such guidelines have been established by the American Society of Anesthesiologists [<a href="#rid27">27</a>] and adopted by the Joint Commission on Accreditation of Healthcare Organizations [<a href="#rid28">28</a>]. These guidelines dictate the safety monitoring requirements and specific agents that can be used for procedural analgesia, as some of the more potent opioids (eg, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>) or anesthetics (eg, <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>) may result in excessive sedation. Deep sedation and general anesthesia warrant a qualified anesthesia provider being present to administer sedative agents and safely monitor the patient. This type of sedation requires an operating room environment and is not suitable for bedside care in a ward. </p><p>Patient requirements for sedation and analgesia during dressing changes should therefore be reviewed regularly and stepped down appropriately. Full use of multimodal analgesic strategies, including nerve blocks, should be considered in order to reduce sedative requirements. Nonpharmacologic techniques (eg, information provision, distraction, relaxation) serve as an essential adjunct to pharmacologic management [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3527578356"><span class="h3">Pharmacologic approaches</span><span class="headingEndMark"> — </span>Typical pharmacologic analgesic regimens for procedural care include opioids, benzodiazepines, and low doses of anesthetic agents such as <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a> and <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>. Any drugs used should ideally have a rapid onset and short duration of action. </p><p>Local anesthetic placed to reduce sensation to a limb or area of the trunk has an important role in managing procedural pain. Local anesthetic can be placed as a single shot to last from 12 to 24 hours, or a catheter can be placed to allow for a continuous infusion of anesthetic for several days. Placement usually requires the use of ultrasound by an anesthesia provider experienced in regional anesthetic techniques [<a href="#rid7">7</a>].</p><p>When administered by appropriately trained and experienced personnel (eg, anesthesia providers), <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> is a safe and effective alternative for managing procedural pain [<a href="#rid30">30,31</a>]. Propofol is particularly advantageous as it can be titrated to effect both in terms of level of consciousness and duration of action using continuous IV infusion techniques and has the additional benefit of a rapid awakening with a minimal risk of nausea. However, propofol is more rapidly cleared and has a higher volume of distribution in burn patients, necessitating careful increases in dose [<a href="#rid32">32,33</a>].</p><p>The following illustrate the pharmacologic approaches to procedural pain, based upon anticipated severity of pain:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor procedure pain</strong> – Minor procedures may require analgesia and/or sedation, particularly for children. These procedures include removal of numerous staples from grafted sites, meticulous wound care of recently grafted sites and/or donor sites, and wound care involving the face and/or neck. A well-timed dose of oral analgesia (eg, <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> given 20 to 30 minutes prior) with or without IV boluses titrated during the procedure may provide adequate analgesia. Oral or intranasal <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> is an option for pediatric burn patients without IV access [<a href="#rid34">34,35</a>]. However, ketamine use is limited by the potential risk of associated emergence delirium reactions (5 to 30 percent incidence), particularly in older adults. Intranasal <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> has been used in pediatric patients [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild-to-moderate procedural pain</strong> – IV and inhalation medications have a rapid onset of action and a short duration of activity, while oral agents have a prolonged onset of action and duration. Inhalation anesthetics can be used if IV access is not possible. The following oral, IV, and inhaled analgesics are used to control mild-to-moderate procedural pain [<a href="#rid34">34,37-42</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonopioid analgesics, anti-inflammatory agents (eg, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>IV opioid analgesics (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>) </p><p class="bulletIndent2"><span class="glyph">•</span>IV anesthetic agents (eg, <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>, <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a>, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>) </p><p class="bulletIndent2"><span class="glyph">•</span>Orally administered opioid analgesics (eg, <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Oral <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> </p><p class="bulletIndent2"><span class="glyph">•</span>Oral <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Inhaled <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a> </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe procedural pain</strong> – General anesthesia, deep sedation, or regional anesthesia is useful for severely painful dressing changes or ones that require extreme cooperation in a noncompliant patient (eg, face debridement in a young child) [<a href="#rid43">43,44</a>].</p><p></p><p class="headingAnchor" id="H175472627"><span class="h3">Nonpharmacologic approaches</span><span class="headingEndMark"> — </span>Nonpharmacologic approaches have included the following</p><p class="bulletIndent1"><span class="glyph">●</span>Relaxation techniques including meditation, progressive muscle relaxation, deep breathing, and guided imagery</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypnosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distraction – media (iPad games, videos, etc.), bubbles, songs, virtual reality [<a href="#rid45">45</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Information provision </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive restructuring</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced coping skills </p><p></p><p></p><p>One of the most useful nonpharmacologic analgesic techniques in this setting is information provision, so that patients understand and anticipate both the increase and temporary nature of the postoperative pain. (See  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Information provision'</a>.) </p><p class="headingAnchor" id="H13088242"><span class="h2">Chronic pain</span><span class="headingEndMark"> — </span>Pain is considered chronic if it exists between three to six months after the wound has healed. Chronic pain is associated with a reduction in quality of life. The study of chronic pain and hyperalgesia in the burn patient population is in the early stages of investigation, and the pathophysiology remains poorly understood [<a href="#rid46">46</a>]. Retrospective reviews found that 33 to 50 percent of burn patients have chronic pain that persists for years after the burns are healed [<a href="#rid47">47-50</a>]. </p><p>The most common form of chronic pain is neuropathic pain. Neuropathic pain is the result of damage sustained by the nerve endings in the skin. Other causes of chronic pain are likely from musculoskeletal pain associated with deconditioning. Patients report that chronic pain is exacerbated by temperature change, dependent position, or weight-bearing activities. (See  <a class="medical medical_review" href="/z/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults", section on 'Pharmacologic therapy for neuropathic pain, or nociplastic or centralized pain'</a>.)</p><p>No data from randomized trials have identified the optimal management of chronic pain in burn patients. Chronic pain is best managed with nonopioid analgesics and nonpharmacologic approaches. Extreme caution should be taken if opioids are to be used for chronic pain, with careful supervision for safety and adjustments of the doses and dosing schedule based upon response. Medication options for chronic neuropathic pain include <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid51">51</a>], <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> [<a href="#rid52">52</a>], and <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a> [<a href="#rid53">53</a>]. NSAIDs may also be an effective nonopioid analgesic. (See  <a class="medical medical_review" href="/z/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults"</a>.)</p><p>Nonpharmacologic approaches should focus on the impact of chronic pain. These approaches include cognitive behavioral strategies, such as distraction techniques, relaxation, and mindfulness-based stress reduction that can target healthy lifestyle choices and adaptive thinking styles. (See  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Nonpharmacologic treatment options'</a>.)</p><p class="headingAnchor" id="H201830792"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118305.html" rel="external">"Society guideline links: Chronic pain management"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118304.html" rel="external">"Society guideline links: Acute pain management"</a>.)</p><p class="headingAnchor" id="H13088249"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Pain management is a central component of the treatment of patients with burns. Despite advances in various aspects of burn care, control of burn pain is often inadequate during the acute and chronic rehabilitation phases of burn care. Pain is among the most common causes of distress during the first year after recovery and, hence, should be aggressively managed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burn pain management</strong> – Optimal management of burn pain requires a structured approach that incorporates both pharmacologic and nonpharmacologic therapies, targets the specific clinical pain settings unique to the burn patient, and is individualized to meet specific patient needs and institutional capabilities. A burn pain paradigm can be used to guide management of the different phases and variability of burn pain. This paradigm is based upon five phases of burn pain occurrence: background, procedural, breakthrough, postoperative, and chronic pain. (See <a class="local">'Challenges in managing burn pain'</a> above and <a class="local">'Burn pain paradigm'</a> above and <a class="local">'Paradigm-based management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Background pain and breakthrough pain</strong> – For background pain management, the combination of pharmacologic and nonpharmacologic techniques can be used. We suggest using a multimodal approach to analgesic drug therapy as detailed above. Frequent reevaluation of drug therapy to monitor for efficacy, side effects, and tolerance is recommended. When pain exceeds background pain management adjustments to the pharmacologic and/or nonpharmacologic pain management should be made after a thorough history and examination to determine the most likely cause. (See <a class="local">'Background pain'</a> above and <a class="local">'Breakthrough pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Procedural pain</strong> – For procedural pain management (eg, dressing changes), the combination of pharmacologic and nonpharmacologic techniques can be used. The approach depends on the anticipated pain caused by the procedure. For procedures that are severely painful, we suggest general or regional anesthesia (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For mildly-to-moderately painful procedures, a combination of analgesic and anxiolytic drugs with rapid onset and short duration along with nonpharmacologic techniques (eg, hypnosis, information provision) may be sufficient  (<a class="graphic graphic_table graphicRef59472" href="/z/d/graphic/59472.html" rel="external">table 1</a>). For procedures that cause minor pain, mild pharmacologic sedation with nonpharmacologic approaches will usually suffice. (See <a class="local">'Procedural pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postoperative pain</strong> – For postoperative pain management, a transient increase in dosing of opioids and the use of regional anesthetics can be added as needed. We suggest using intravenous (IV) <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> or <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> for the critical care setting (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For noncritical care settings, and when IV access is not available, postoperative pain can be managed with <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>. Nonpharmacologic techniques that were effective prior to the operation and that matched a person's coping style should continue to be used in the postoperative period. A particularly helpful technique is information provision. (See <a class="local">'Postoperative pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic pain</strong> – For chronic and neuropathic pain management, the combination of pharmacologic and nonpharmacologic techniques may be useful in managing pain. We suggest nonopioid regimens, with adjustments of the doses and dosing schedule based upon response (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Nonpharmacologic options, such as cognitive distraction, mindfulness-based stress reduction, hypnosis, and relaxation techniques, should focus on decreasing the impact of chronic pain and enhancing quality of life. (See <a class="local">'Chronic pain'</a> above.)</p><p></p><p class="headingAnchor" id="H335891367"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledges Sam R Sharar, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Retrouvey H, Shahrokhi S. Pain and the thermally injured patient-a review of current therapies. J Burn Care Res 2015; 36:315.</a></li><li><a class="nounderline abstract_t">Askay SW, Stricklin M, Carrougher GJ, et al. Using QMethodology to identify reasons for distress in burn survivors postdischarge. J Burn Care Res 2009; 30:83.</a></li><li><a class="nounderline abstract_t">Wiechman Askay S, Patterson DR, Sharar SR, et al. Pain management in patients with burn injuries. Int Rev Psychiatry 2009; 21:522.</a></li><li class="breakAll">Burn Pain: A Unique Challenge. Pain Clinical Updates. International Association for the Study of Pain. Vol IX, Issue 1. March 2001. www.iasp-pain.org.</li><li class="breakAll">Patterson DR, Sharar SR. Burn pain. In: Bonica's Management of Pain, 4th edition, Fishman SM, Ballantyne JC, Rathmell JP (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. p.754.</li><li><a class="nounderline abstract_t">Kealey GP. Pharmacologic management of background pain in burn victims. J Burn Care Rehabil 1995; 16:358.</a></li><li><a class="nounderline abstract_t">Sheckter CC, Stewart BT, Barnes C, et al. Techniques and strategies for regional anesthesia in acute burn care-a narrative review. Burns Trauma 2021; 9:tkab015.</a></li><li><a class="nounderline abstract_t">Furman WR, Munster AM, Cone EJ. Morphine pharmacokinetics during anesthesia and surgery in patients with burns. J Burn Care Rehabil 1990; 11:391.</a></li><li><a class="nounderline abstract_t">Morgan M, Deuis JR, Frøsig-Jørgensen M, et al. Burn Pain: A Systematic and Critical Review of Epidemiology, Pathophysiology, and Treatment. Pain Med 2018; 19:708.</a></li><li><a class="nounderline abstract_t">Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 2009; 89:707.</a></li><li><a class="nounderline abstract_t">Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14:145.</a></li><li><a class="nounderline abstract_t">Gordon DB. Acute pain assessment tools: let us move beyond simple pain ratings. Curr Opin Anaesthesiol 2015; 28:565.</a></li><li><a class="nounderline abstract_t">Faucher L, Furukawa K. Practice guidelines for the management of pain. J Burn Care Res 2006; 27:659.</a></li><li><a class="nounderline abstract_t">Sheridan RL, Hinson M, Nackel A, et al. Development of a pediatric burn pain and anxiety management program. J Burn Care Rehabil 1997; 18:455.</a></li><li><a class="nounderline abstract_t">Gamst-Jensen H, Vedel PN, Lindberg-Larsen VO, Egerod I. Acute pain management in burn patients: appraisal and thematic analysis of four clinical guidelines. Burns 2014; 40:1463.</a></li><li><a class="nounderline abstract_t">Gibbons J, Honari SR, Sharar SR, et al. Opiate-induced respiratory depression in young pediatric burn patients. J Burn Care Rehabil 1998; 19:225.</a></li><li><a class="nounderline abstract_t">Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep 2017; 66:265.</a></li><li><a class="nounderline abstract_t">Carrougher GJ, Ptacek JT, Sharar SR, et al. Comparison of patient satisfaction and self-reports of pain in adult burn-injured patients. J Burn Care Rehabil 2003; 24:1.</a></li><li><a class="nounderline abstract_t">Smith HS, Peppin JF. Toward a systematic approach to opioid rotation. J Pain Res 2014; 7:589.</a></li><li><a class="nounderline abstract_t">Polychronopoulou E, Kuo YF, Wilkes D, Raji MA. Prescribing of Gabapentinoids with or without opioids after burn injury in the US, 2012-2018. Burns 2022; 48:293.</a></li><li><a class="nounderline abstract_t">Cuignet O, Mbuyamba J, Pirson J. The long-term analgesic efficacy of a single-shot fascia iliaca compartment block in burn patients undergoing skin-grafting procedures. J Burn Care Rehabil 2005; 26:409.</a></li><li><a class="nounderline abstract_t">Wasiak J, Mahar PD, McGuinness SK, et al. Intravenous lidocaine for the treatment of background or procedural burn pain. Cochrane Database Syst Rev 2014; :CD005622.</a></li><li><a class="nounderline abstract_t">McGuinness SK, Wasiak J, Cleland H, et al. A systematic review of ketamine as an analgesic agent in adult burn injuries. Pain Med 2011; 12:1551.</a></li><li><a class="nounderline abstract_t">Weisman SJ, Bernstein B, Schechter NL. Consequences of inadequate analgesia during painful procedures in children. Arch Pediatr Adolesc Med 1998; 152:147.</a></li><li><a class="nounderline abstract_t">Thurber CA, Martin-Herz SP, Patterson DR. Psychological principles of burn wound pain in children. I: theoretical framework. J Burn Care Rehabil 2000; 21:376.</a></li><li><a class="nounderline abstract_t">Myers R, Lozenski J, Wyatt M, et al. Sedation and Analgesia for Dressing Change: A Survey of American Burn Association Burn Centers. J Burn Care Res 2017; 38:e48.</a></li><li><a class="nounderline abstract_t">American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002; 96:1004.</a></li><li class="breakAll">The Joint Commission's Pain Standards: Origins and Evolution. The Joint Commission. Available at: https://www.jointcommission.org/-/media/tjc/documents/resources/pain-management/pain_std_history_web_version_05122017pdf.pdf?db=web&amp;hash=E7D12A5C3BE9DF031F3D8FE0D8509580&amp;hash=E7D12A5C3BE9DF031F3D8FE0D8509580 (Accessed on October 14, 2022).</li><li><a class="nounderline abstract_t">Scheffler M, Koranyi S, Meissner W, et al. Efficacy of non-pharmacological interventions for procedural pain relief in adults undergoing burn wound care: A systematic review and meta-analysis of randomized controlled trials. Burns 2018; 44:1709.</a></li><li><a class="nounderline abstract_t">Chen L, Wang M, Xiang H, et al. Prediction of effect-site concentration of sufentanil by dose-response target controlled infusion of sufentanil and propofol for analgesic and sedation maintenance in burn dressing changes. Burns 2014; 40:455.</a></li><li><a class="nounderline abstract_t">Coimbra C, Choinière M, Hemmerling TM. Patient-controlled sedation using propofol for dressing changes in burn patients: a dose-finding study. Anesth Analg 2003; 97:839.</a></li><li><a class="nounderline abstract_t">Yamashita S, Kaneda K, Han TH. Population pharmacokinetics of a propofol bolus administered in patients with major burns. Burns 2010; 36:1215.</a></li><li><a class="nounderline abstract_t">Han TH, Greenblatt DJ, Martyn JA. Propofol clearance and volume of distribution are increased in patients with major burns. J Clin Pharmacol 2009; 49:768.</a></li><li><a class="nounderline abstract_t">Humphries Y, Melson M, Gore D. Superiority of oral ketamine as an analgesic and sedative for wound care procedures in the pediatric patient with burns. J Burn Care Rehabil 1997; 18:34.</a></li><li><a class="nounderline abstract_t">Poonai N, Canton K, Ali S, et al. Intranasal ketamine for procedural sedation and analgesia in children: A systematic review. PLoS One 2017; 12:e0173253.</a></li><li><a class="nounderline abstract_t">Poonai N, Spohn J, Vandermeer B, et al. Intranasal Dexmedetomidine for Procedural Distress in Children: A Systematic Review. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Sharar SR, Bratton SL, Carrougher GJ, et al. A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J Burn Care Rehabil 1998; 19:516.</a></li><li><a class="nounderline abstract_t">Sharar SR, Carrougher GJ, Selzer K, et al. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J Burn Care Rehabil 2002; 23:27.</a></li><li><a class="nounderline abstract_t">Prakash S, Fatima T, Pawar M. Patient-controlled analgesia with fentanyl for burn dressing changes. Anesth Analg 2004; 99:552.</a></li><li><a class="nounderline abstract_t">Choiniere M, Grenier R, Paquette C. Patient-controlled analgesia: a double-blind study in burn patients. Anaesthesia 1992; 47:467.</a></li><li><a class="nounderline abstract_t">Owens VF, Palmieri TL, Comroe CM, et al. Ketamine: a safe and effective agent for painful procedures in the pediatric burn patient. J Burn Care Res 2006; 27:211.</a></li><li><a class="nounderline abstract_t">Wasiak J, Spinks A, Costello V, et al. Adjuvant use of intravenous lidocaine for procedural burn pain relief: a randomized double-blind, placebo-controlled, cross-over trial. Burns 2011; 37:951.</a></li><li><a class="nounderline abstract_t">Dimick P, Helvig E, Heimbach D, et al. Anesthesia-assisted procedures in a burn intensive care unit procedure room: benefits and complications. J Burn Care Rehabil 1993; 14:446.</a></li><li><a class="nounderline abstract_t">Powers PS, Cruse CW, Daniels S, Stevens BA. Safety and efficacy of debridement under anesthesia in patients with burns. J Burn Care Rehabil 1993; 14:176.</a></li><li><a class="nounderline abstract_t">Luo H, Cao C, Zhong J, et al. Adjunctive virtual reality for procedural pain management of burn patients during dressing change or physical therapy: A systematic review and meta-analysis of randomized controlled trials. Wound Repair Regen 2019; 27:90.</a></li><li><a class="nounderline abstract_t">Roy TK, Uniyal A, Akhilesh, Tiwari V. Multifactorial pathways in burn injury-induced chronic pain: novel targets and their pharmacological modulation. Mol Biol Rep 2022; 49:12121.</a></li><li><a class="nounderline abstract_t">Choinière M, Melzack R, Papillon J. Pain and paresthesia in patients with healed burns: an exploratory study. J Pain Symptom Manage 1991; 6:437.</a></li><li><a class="nounderline abstract_t">Malenfant A, Forget R, Amsel R, et al. Tactile, thermal and pain sensibility in burned patients with and without chronic pain and paresthesia problems. Pain 1998; 77:241.</a></li><li><a class="nounderline abstract_t">Dauber A, Osgood PF, Breslau AJ, et al. Chronic persistent pain after severe burns: a survey of 358 burn survivors. Pain Med 2002; 3:6.</a></li><li><a class="nounderline abstract_t">Klifto KM, Dellon AL, Hultman CS. Prevalence and associated predictors for patients developing chronic neuropathic pain following burns. Burns Trauma 2020; 8:tkaa011.</a></li><li><a class="nounderline abstract_t">Gray P, Kirby J, Smith MT, et al. Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial. Pain 2011; 152:1279.</a></li><li><a class="nounderline abstract_t">Gray P, Williams B, Cramond T. Successful use of gabapentin in acute pain management following burn injury: a case series. Pain Med 2008; 9:371.</a></li><li><a class="nounderline abstract_t">Najafi A, Zeinali Nejad H, Nikvarz N. Evaluation of the analgesic effects of duloxetine in burn patients: An open-label randomized controlled trial. Burns 2019; 45:598.</a></li></ol></div><div id="topicVersionRevision">Topic 16505 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24823343" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pain and the thermally injured patient-a review of current therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19060733" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Using QMethodology to identify reasons for distress in burn survivors postdischarge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19919205" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pain management in patients with burn injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19919205" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pain management in patients with burn injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19919205" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pain management in patients with burn injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7642681" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacologic management of background pain in burn victims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34285927" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Techniques and strategies for regional anesthesia in acute burn care-a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2246307" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Morphine pharmacokinetics during anesthesia and surgery in patients with burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29036469" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Burn Pain: A Systematic and Critical Review of Epidemiology, Pathophysiology, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19342617" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Models and mechanisms of hyperalgesia and allodynia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412369" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A comprehensive review of opioid-induced hyperalgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26237235" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute pain assessment tools: let us move beyond simple pain ratings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16998398" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Practice guidelines for the management of pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9313130" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Development of a pediatric burn pain and anxiety management program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25277698" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute pain management in burn patients: appraisal and thematic analysis of four clinical guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9622467" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Opiate-induced respiratory depression in young pediatric burn patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301454" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2006-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543984" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of patient satisfaction and self-reports of pain in adult burn-injured patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25378948" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Toward a systematic approach to opioid rotation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34991930" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prescribing of Gabapentinoids with or without opioids after burn injury in the US, 2012-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151286" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The long-term analgesic efficacy of a single-shot fascia iliaca compartment block in burn patients undergoing skin-grafting procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25321859" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intravenous lidocaine for the treatment of background or procedural burn pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880111" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A systematic review of ketamine as an analgesic agent in adult burn injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9491040" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Consequences of inadequate analgesia during painful procedures in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10935822" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Psychological principles of burn wound pain in children. I: theoretical framework.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27606558" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sedation and Analgesia for Dressing Change: A Survey of American Burn Association Burn Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964611" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Practice guidelines for sedation and analgesia by non-anesthesiologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964611" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Practice guidelines for sedation and analgesia by non-anesthesiologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29287729" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy of non-pharmacological interventions for procedural pain relief in adults undergoing burn wound care: A systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993735" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prediction of effect-site concentration of sufentanil by dose-response target controlled infusion of sufentanil and propofol for analgesic and sedation maintenance in burn dressing changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12933412" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Patient-controlled sedation using propofol for dressing changes in burn patients: a dose-finding study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20510522" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Population pharmacokinetics of a propofol bolus administered in patients with major burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553403" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Propofol clearance and volume of distribution are increased in patients with major burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063785" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Superiority of oral ketamine as an analgesic and sedative for wound care procedures in the pediatric patient with burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28319161" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intranasal ketamine for procedural sedation and analgesia in children: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31862730" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intranasal Dexmedetomidine for Procedural Distress in Children: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848042" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11803309" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15271737" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Patient-controlled analgesia with fentanyl for burn dressing changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616080" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Patient-controlled analgesia: a double-blind study in burn patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16566568" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ketamine: a safe and effective agent for painful procedures in the pediatric burn patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21497022" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adjuvant use of intravenous lidocaine for procedural burn pain relief: a randomized double-blind, placebo-controlled, cross-over trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8408170" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Anesthesia-assisted procedures in a burn intensive care unit procedure room: benefits and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501106" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety and efficacy of debridement under anesthesia in patients with burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30480854" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adjunctive virtual reality for procedural pain management of burn patients during dressing change or physical therapy: A systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35842856" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Multifactorial pathways in burn injury-induced chronic pain: novel targets and their pharmacological modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1940489" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pain and paresthesia in patients with healed burns: an exploratory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808349" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tactile, thermal and pain sensibility in burned patients with and without chronic pain and paresthesia problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15102213" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic persistent pain after severe burns: a survey of 358 burn survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32377542" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalence and associated predictors for patients developing chronic neuropathic pain following burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21398038" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18366516" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Successful use of gabapentin in acute pain management following burn injury: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30470568" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Evaluation of the analgesic effects of duloxetine in burn patients: An open-label randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
